Company intelligence / Profile preview

Circurna

Galveston, Texas, United States

Ownership: Private
Development stage: Other

Overview

Circurna is advancing its circular RNA (ciRNA™/emxRNA™) platforms designed to improve stability, protein expression, and immune response for vaccines and therapeutics, focusing on oncology, infectious diseases, and autoimmune disorders. Supported by NIH and CEPI, the platform enables thermostable nanoparticle formulations and enhanced delivery. Clinical results have not been disclosed yet; the company is in pre-clinical partnership-based research phases.

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: Circular RNARNA therapyLipid nanoparticle delivery therapyProtein
Industry: Biotech

Partnerships

Coalition for Epidemic Preparedness Innovations (CEPI)National Institutes of Health (NIH)GATC Health

Beyond the preview

Go deeper on Circurna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Circurna.

Explore the full profile